ArticleWorld journal of urology2026
Efficacy and safety of cytoreductive nephrectomy combined with thrombectomy in metastatic renal cell carcinoma with venous tumor thrombus: a real-world study based on inverse probability of treatment weighting.
Article in World journal of urology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundCytoreductive nephrectomy (CN) combined with thrombectomy remains controversial for metastatic renal cell carcinoma with venous tumor thrombus (mRCC-VTT), and optimal patient selection remains undefined.
methodsWe retrospectively analyzed 238 patients with RCC-VTT treated at a single center between February 2006 and December 2023. Patients were stratified as non-metastatic surgical (nmRCC-VTT-S, n = 135), metastatic surgical (mRCC-VTT-S, n = 53), or metastatic non-surgical (mRCC-VTT-NS, n = 50). Inverse probability of treatment weighting (IPTW) was used to reduce measured confounding. Perioperative outcomes, OS, PFS, subgroup heterogeneity, and 3-month landmark sensitivity analyses were evaluated.
resultsAfter IPTW adjustment, perioperative outcomes were comparable between metastatic and non-metastatic surgical cohorts (all P > 0.05). In the metastatic cohort, surgery was associated with longer OS than non-surgical management (P = 0.027), and this association remained significant in the 3-month landmark analysis after re-estimating IPTW (P = 0.018). PFS showed no significant difference after primary IPTW adjustment (P = 0.517) and showed only a non-significant favorable trend after landmark IPTW adjustment (P = 0.064). Mayo level modified the association between surgery and OS (P for interaction < 0.001) and PFS (P for interaction = 0.034). For OS, surgery was associated with longer survival in Mayo 0-II thrombi (HR 0.56, P = 0.045), whereas patients with Mayo III-IV thrombi had worse outcomes after surgery (HR 6.22, P = 0.016).
conclusionsCN combined with thrombectomy appeared feasible and was associated with improved OS in selected patients with mRCC-VTT, particularly those with low-level thrombi. Mayo level should inform surgical decision-making, and systemic therapy-first strategies should be considered for high-level thrombi.
Indexed as
Identifiers
42472396What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.